In the ovarian cancer trial performed in Gothenburg, Sweden, patients were treated intraperitoneally with 211At-MX35(Fab)2 antibody fragment, targeting the sodium-dependent phosphate transport protein 2B (NaPi2b). This evidence concerns the gene SLC34A2 and ovarian carcinoma.